RMC No. 112-2022: FDA-Endorsed Updates to VAT-Exempt Medicines Affecting Tuberculosis Treatments
RMC No. 112-2022 updates the VAT-exempt medicines list under the CREATE Act, adding tuberculosis medicines and removing COVID-19 medicines, affecting tax compliance for healthcare providers. Businesses in the pharmaceutical and healthcare sectors must immediately update their records and compliance processes due to the newly endorsed changes to the VAT-exempt medicines list. Certain medicines prescribed for […]